Literature DB >> 16703599

Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines.

Ann Maria McCrohan1, Colm Morrissey, Conor O'Keane, Niall Mulligan, Chanel Watson, James Smith, John M Fitzpatrick, R William G Watson.   

Abstract

BACKGROUND: The profound reduction in serum dihydrotestosterone (DHT) observed with the dual 5 alpha-reductase inhibitor (5ARI) dutasteride makes it an attractive agent for prostate cancer therapy. The objective of the current study was to determine whether dutasteride would induce apoptosis in a range of prostate epithelial cell lines and primary cultures.
METHODS: Both human prostate androgen-sensitive cell lines (PwR-1E, PNT-2, LNCaP, and PC3[AR2]) and an androgen-independent cell line (PC-3) were grown to confluence. Primary epithelial cells extracted from fresh prostate cancer radical prostatectomy specimens also were grown to confluence under optimal conditions. Total cellular protein was extracted to confirm cytokeratin 18 and antihuman alpha-methylacyl-CoA racemase (AMACR) expression of the primary cells. Apoptosis was assessed by propidium iodide DNA staining and flow cytometry after 24 hours of culture in from 0 microM to 10 microM of dutasteride.
RESULTS: Dutasteride induced a dose-dependent increase in apoptosis in the androgen-sensitive prostate cell lines PwR-1E, PNT-2, and LNCaP and in the androgen receptor-expressing PC3(AR2) cell line. However, there was no significant apoptosis noted in the parental PC-3 cells. Of 16 primary epithelial cultures that were treated, 7 cultures were induced to undergo apoptosis, and 9 cultures were unresponsive. All primary cultures were positive for cytokeratin 18 expression, confirming their epithelial phenotype. Responder epithelial cells were positive for AMACR expression.
CONCLUSIONS: The results of the current study confirmed that dutasteride differentially induced apoptosis in a subset of prostate cell lines and primary prostate epithelial cells. Understanding the cellular phenotype may indicate susceptible cells. Copyright 2006 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16703599     DOI: 10.1002/cncr.21938

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

Review 1.  [What comes after docetaxel?].

Authors:  C-H Ohlmann; M Stöckle
Journal:  Urologe A       Date:  2010-01       Impact factor: 0.639

Review 2.  [Third generation anti-androgen therapy of advanced prostate cancer].

Authors:  C-H Ohlmann; J Kamradt; M Stöckle
Journal:  Urologe A       Date:  2012-04       Impact factor: 0.639

Review 3.  Dutasteride: a review of its use in the management of prostate disorders.

Authors:  Susan J Keam; Lesley J Scott
Journal:  Drugs       Date:  2008       Impact factor: 9.546

4.  Nordihydroguaiaretic acid inhibits transforming growth factor beta type 1 receptor activity and downstream signaling.

Authors:  Fusheng Li; Johnny D Pham; Marc O Anderson; Jack F Youngren
Journal:  Eur J Pharmacol       Date:  2009-06-17       Impact factor: 4.432

5.  Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs.

Authors:  Joseph E Blecha; Marc O Anderson; Jennifer M Chow; Christle C Guevarra; Celia Pender; Cristina Penaranda; Marianna Zavodovskaya; Jack F Youngren; Clifford E Berkman
Journal:  Bioorg Med Chem Lett       Date:  2007-04-29       Impact factor: 2.823

6.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

7.  Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.

Authors:  Amanda J O'Neill; Maria Prencipe; Catherine Dowling; Yue Fan; Laoighse Mulrane; William M Gallagher; Darran O'Connor; Robert O'Connor; Aoife Devery; Claire Corcoran; Sweta Rani; Lorraine O'Driscoll; John M Fitzpatrick; R William G Watson
Journal:  Mol Cancer       Date:  2011-10-07       Impact factor: 27.401

8.  The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer.

Authors:  Karen Hanrahan; Amanda O'Neill; Maria Prencipe; Jane Bugler; Lisa Murphy; Aurelie Fabre; Martin Puhr; Zoran Culig; Keefe Murphy; R William Watson
Journal:  Mol Oncol       Date:  2017-01-30       Impact factor: 6.603

9.  Pathogenesis of prostate cancer and hormone refractory prostate cancer.

Authors:  J S Girling; H C Whitaker; I G Mills; D E Neal
Journal:  Indian J Urol       Date:  2007-01

10.  Synthesis of pregnane derivatives, their cytotoxicity on LNCap and PC-3 cells, and screening on 5alpha-reductase inhibitory activity.

Authors:  Sujeong Kim; Eunsook Ma
Journal:  Molecules       Date:  2009-11-17       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.